Fulgent Genetics Net Worth

Fulgent Genetics Net Worth Analysis

Fulgent Genetics Target Price Consensus

Fulgent Genetics Target Price Projection

Fulgent Genetics' current and average target prices are 18.63 and 22.67, respectively. The current price of Fulgent Genetics is the price at which Fulgent Genetics is currently trading. On the other hand, Fulgent Genetics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Fulgent Genetics and the information provided on this page.

Know Fulgent Genetics' Top Institutional Investors

Note, although Fulgent Genetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Fulgent Genetics' market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 540.37 M.

Project Fulgent Genetics' profitablity

The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.27.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate Fulgent Genetics' management efficiency

Fulgent Genetics has return on total asset (ROA) of (0.0369) % which means that it has lost $0.0369 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0372) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.04 in 2025. Return On Capital Employed is likely to drop to -0.07 in 2025. At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 6.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 52.2 M in 2025.

Fulgent Genetics Corporate Filings

Fulgent Genetics time-series forecasting models is one of many Fulgent Genetics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fulgent Genetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Fulgent Genetics Earnings Estimation Breakdown

The calculation of Fulgent Genetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Fulgent Genetics is estimated to be -0.1379 with the future projection ranging from a low of -0.16 to a high of -0.1037. Please be aware that this consensus of annual earnings estimates for Fulgent Genetics is based on EPS before non-recurring items and includes expenses related to employee stock options.

Fulgent Genetics Earnings Projection Consensus

Fulgent Genetics Earnings History

Earnings estimate consensus by Fulgent Genetics analysts from Wall Street is used by the market to judge Fulgent Genetics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Fulgent Genetics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods. At this time, Fulgent Genetics' Retained Earnings are comparatively stable compared to the past year. Retained Earnings Total Equity is likely to gain to about 794 M in 2025, despite the fact that Earnings Yield is likely to grow to (0.07). Common Stock Shares Outstanding is likely to drop to about 24.9 M in 2025. Net Income Applicable To Common Shares is likely to drop to about 101.5 M in 2025.

Hype Prediction Low Estimated High 15.30 18.63 21.96 Details

Intrinsic Valuation Low Real High 17.54 20.87 24.20 Details

Naive Forecast Low Next High 14.14 17.48 20.81 Details

3 Analysts Consensus Low Target High 20.63 22.67 25.16 Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Fulgent Genetics. Your research has to be compared to or analyzed against Fulgent Genetics' peers to derive any actionable benefits. When done correctly, Fulgent Genetics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Fulgent Genetics. Note that many institutional investors and large investment bankers can move markets due to the volume of Fulgent assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Fulgent Genetics. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Fulgent Genetics' stock price in the short term.

Fulgent Genetics Earnings per Share Projection vs Actual

Actual Earning per Share of Fulgent Genetics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Fulgent Genetics predict the company's earnings will be in the future. The higher the earnings per share of Fulgent Genetics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Fulgent Genetics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Fulgent Genetics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Fulgent Genetics should always be considered in relation to other companies to make a more educated investment decision.

Fulgent Quarterly Analyst Estimates and Surprise Metrics

Fulgent Genetics Corporate Management

Additional Tools for Fulgent Stock Analysis